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A controlled study of the effect of indomethacin in uremic pericarditis.
To determine the impact of indomethacin on the course of uremic
pericarditis we performed a prospective, double blind study in which 24
patients with endstage chronic renal failure and pericarditis randomly
received indomethacin, 25 mg four times daily, (11 patients) or a
placebo (13 patients) for a 3-week period. All patients received perito-
neal or hemodialysis treatment concurrently with the study drug. In
contrast to the placebo, indomethacin produced an immediate and
sustained reduction of fever in all but one patient. On the other hand,
indomethacin had no effect on the duration of chest pain (mean days
sa: placebo 1.4 0.6, indomethacin 5.5 3.3), duration of pericardial
friction rub (placebo 10.3 1.7, indomethacin 16.0 3.8), or on the
amount of pericardial effusion. Further, indomethacin did not diminish
the need for invasive surgical procedures for relief of tamponade (three
of 13 placebo patients, two of 11 indomethacin patients) or result in
decreased mortality rate. Death (not due to pericarditis) occurred in two
patients treated with indomethacin and one patient who received the
placebo. In our patients pericarditis encompassed a wide spectrum
ranging from a mild illness of several days duration to a painful and
debilitating disease lasting weeks and requiring surgical intervention.
Although the size of our population prohibits definitive conclusions, it
would appear that, except for fever, the manifestations and natural
history of this illness are unaffected by indomethacin.
Une étude contrôlée de l'effet de l'indométhacine dans Ia péricardite
urémique. Determiner l'effet de l'indométhacine sur l'évolution de La
péricardite urCmique, nous avons effectué une étude prospective, en
double insu, dans laquelle 24 malades avec une insuffisance rénale
chronique terminale et une péricardite ont recu au hasard 25 mg quatre
fois par jour (11 malades) d'indométhacine ou de placebo (13 malades)
pendant une période de 3 semaines. Tous les malades étaient en dialyse
péritonéale ou en hemodialyse en méme temps que l'étude du médica-
ment. Par rapport au placebo, l'indomCthacine a entrainé une reduction
immediate et prolongee de Ia fièvre chez tous les malades sauf un.
Cependant, l'indomdthacine n'a pas eu d'effet sur Ia durée de Ia douleur
thoracique (nombre moyen dejours SE: placebo 1,4 0,6, indométh-
acme 5,5 3,3), Ia durCe du frottement pCricardique (placebo 10,3
1,7, indométhacine 16,0 3,8), ou sur l'importance de l'dpanchement.
En outre, l'indométhacine n'a pas diminué Ia nécessité de gestes
chirurgicaux invasifs nécessaires pour améliorer Ia tamponnade (trois
du 13 malades placebo, deux du 11 malades sous indométhacine), ni n'a
diminué le taux de mortalité. La mort (non dOe a Ia péricardite) est
survenue chez deux malades traités avec I'indométhacine et chez un
malade qui avait recu le placebo. Chez nos malades, Ia péricardite était
caractérisée par un large spectre allant d'une maladie de gravité
moyenne durant plusieurs jours a une maladie douloureuse et débili-
tante durant des semaines et ndcessitant une intervention chirurgicale.
Bien que Ia taille de notre population interdise des conclusions défini-
tives, il semble apparaltre qu'à l'exception de Ia fièvre, les manifesta-
tions et l'histoire naturelle de cette maladie ne sont pas affectées par
l'indométhacine.
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Symptomatic pericarditis occurs in 7 to 20% of patients in a
chronic dialysis population [1—5], with a mortality rate reported
as ranging from 12 to 40% [61. At present, there is no concensus
on how to treat patients with pericarditis associated with
chronic renal failure, Most investigators have advocated in-
creasing dialysis frequency [1—3, 5, 6] and the use of regional
heparinization for patients already receiving hemodialysis,
while others have suggested changing dialysis modes from
hemodialysis to peritoneal dialysis [2, 4, 7]. Systemic cortico-
steroids have been suggested, but enthusiasm for their use has
dampened following reports of significant toxicity and uncertain
therapeutic benefit [1, 6].
In 1975, Minuth et al [8] described eight patients with chronic
renal failure whose signs and symptoms of pericarditis abated
coincidence with the use of the anti-inflammatory drug, indo-
methacin since that study [9—11], no controlled study of the
efficacy of this drug has been reported. Therefore, we per-
formed a prospective, double blind, randomized trial to deter-
mine the impact of indomethacin in uremic pericarditis. In
addition, the prospective nature of our trial gave us a unique
chance to describe the early natural history of this disease.
Methods
Patients in the study had chronic renal failure and were being
treated in the Baltimore City Hospitals, Baltimore, Maryland,
dialysis units and renal clinics. Over a 3-year span, all patients
who developed signs or symptoms of pericarditis and who
would give informed consent were entered into the study
protocol. A total of 30 patients were diagnosed as having uremic
pericarditis (for definition, see below), and 24 entered the
study. Six patients were not included in the study: three of
these patients refused or could not give informed consent; two
patients had symptoms and signs of pericarditis abate before the
protocol drug could be given; one patient previously had
infectious pericarditis and was excluded from the study.
For purposes of entrance into the study protocol, pericarditis
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was defined by the presence of an unequivocal pericardial
friction rub heard by two or more physicians, or, in the absence
of friction rub, chest pain consistent with pericarditis and
echocardiographic evidence of pericardial effusion. No patient
was entered into the study who had only radiologic or sonogra-
phic evidence of pericardial effusion.
As soon as possible after the diagnosis of pericarditis, pa-
tients were hospitalized and underwent a complete history and
physical examination. Admission testing included: EKG, chest
x-ray, B mode echocardiography (performed in the supine
position), lupus preparation, antinuclear antibody, rheumatoid
factor, skin tests for tuberculosis and mumps, complete blood
count, blood culture, and biochemical profile.
Following informed consent, patients were stratified accord-
ing to whether or not they had received prior dialysis and
according to the size of pericardial effusion on initial echocar-
diogram. A posterior effusion of less than 1 cm in diameter was
considered "small"; a posterior effusion of greater than 1 cm
was considered "moderate"; combined anterior and posterior
effusion was considered "large."
Following stratification, patients were randomized (method
of random numbers) by the Pharmacy Department of Baltimore
City Hospitals to receive either indomethacin, 25 mg, or an
identical appearing placebo, every 6 hr. Indomethacin and
placebo were supplied by Merck, Sharpe and Dohme, Inc.,
Montreal, Quebec, Canada. After 2 weeks, the dose schedule
was reduced from every 6 hr to every 8 hr, and further tapered
over 7 days until discontinuation of the capsule on day 21.
Neither the patient nor the physicians knew the identity of the
drug until after statistical comparisons between the groups were
made.
The patients were examined daily by one of the authors and
members of the housestaff. Daily records were kept for each
patient and included temperature, pulse, blood pressure, pres-
ence or absence of pericardial rub and of chest pain. Other
clinical signs such as the quantitated pulsus paradoxus were
noted frequently, but not necessarily daily. Chest x-rays,
echocardiograms, complete blood counts, and biochemical pro-
files including liver function tests were performed every 5 to 7
days for 4 weeks following stratification. Potential side effects
of indomethacin including symptoms of nausea, vomiting, and
abdominal pain were monitored daily during the study.
There was no increase in dialysis time for previously dialyzed
patients. Hemodialysis patients were dialyzed 5 to 6 hr three
times weekly using regional heparinization. Peritoneal dialysis
patients were dialyzed three times weekly for a total of 36 to 40
hr. No patients were undergoing continuous ambulatory perito-
neal dialysis (CAPD). Patients not dialyzed before onset of
pericarditis were immediately begun on a regular dialysis sched-
ule as above.
Patients felt to have acute and/or chronic tamponade were
offered surgical intervention (hereafter meant to include pen-
cardiocentesis as well as pericardiectomy). Pericardiectomy
was the procedure of choice during the first half of the study,
but pericardiocentesis with penicardial drainage and instillation
of corticosteroids was subsequently used.
The efficacy of indomethacin or placebo in the treatment of
symptomatic uremic penicarditis was judged in four ways: (1)
duration (expressed as days) of fever, chest pain, and pericardi-
a! friction rub following initiation of drug; (2) changes in volume
of pericardial effusion as reflected by echocardiography at
initiation of the protocol and during week 4 of follow-up, (or
sooner if invasive procedures were required; (3) necessity for
pericardiocentesis or pericardiectomy; (4) mortality.
Statistical comparisons of the two treatment groups were
made by utilizing the Mann-Whitney two sample test statistics,
"U", the x2 test, the Wilcoxon rank sum test, or Student's
test, where applicable.
To test whether the placebo or indomethacin treatment
groups were comparable, prior to initiation of treatment, statis-
tical comparisons were made using the Mann-Whitney two
sample test statistic, "U", the x2 test, and the Wilcoxon rank
sum test.
The protocol was reviewed and approved by the Institutional
Review Board of the Baltimore City Hospitals.
Results
During a 3-year period 24 patients with chronic renal failure
developed symptomatic pericarditis and were entered into the
experimental protocol. Twenty-one patients had been receiving
regular dialysis prior to developing pericarditis, and three
patients were awaiting dialysis. Except for the presence of renal
failure, no etiologic basis for pericarditis was determined in any
patient, although one placebo patient had systemic sclerosis
and one indomethacin patient had previously had a positive
lupus preparation. (There was no evidence of "active" system-
ic lupus erythematosis prior to or at the time of pericarditis). In
addition, two placebo-treated patients had slightly positive tests
for antinuclear antibody, but no other evidence for collagen
vascular disease. No patient was felt to have had acute myocar-
dial infarction as a cause of pericarditis. Two patients in the
placebo group previously had echocardiograms revealing pen-
cardial effusions but never had symptomatic pericardial effu-
sion, and one patient in the indomethacin group had chest pain
and questionable friction rub on one occasion I month prior to
development of documented pericarditis.
After admission to the hospital and stratification, 13 patients
received placebo, 11 patients received indomethacin. No pa-
tient was treated with corticosteroids, aspirin, or other anti-
inflammatory or immunosuppressive agents during the study
protocol, except for the patient with systemic sclerosis, who
had been receiving, and continued to receive, 5 mg of predni-
sone daily.
Success of stratification
Characteristics of the two groups of patients at time of
stratification are listed in Table 1. The groups are comparable
regarding patient characteristics and the clinical setting in
which pericarditis developed. On entrance to the study, all but
one patient had a pericardial friction rub, and all but four
patients, (two in the placebo group, and two in the indometh-
acm group), had chest pain due to pericarditis.
As other authors have noted, there was a high incidence of
extracardiac illness associated with uremic pericarditis. Sixty-
two percent of the patients receiving the placebo and 55% of the
patients receiving indomethacin had a clinical illness or opera-
tive procedure within the week immediately preceeding the
onset of pericarditis. X-ray evidence of pulmonary disease
including pneumonia and/or pleural effusions was common,
occurring in 62% of the patients receiving placebo and 55% of
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Table 1. Patient characteristics at time of admission for pericarditis°
Placebo
2
3 F 25
4 F 58
5 M 53
6 F 40 3
7 M 63 0.75
8 F 26 37
9 M 75 0
10 F 55 8
11 M 63 12
12 F 39 10
13 M 42 3
Illness or
Type of operation
prior preceding onset
dialysis of pericarditis
sis
P Peritonitis
H SepsisH URI0 CHF
H Coil rupture
P None
H URI/AV graft
revision
H UTI/missed dial-
_______ ysis
Pneumonia
andlor
pleural
effusion
difference between the groups in the duration of chest pain prior
to receiving the placebo or indomethacin (mean number of
days: placebo = 1.1 0.3 SE, indomethacin = 1.6 0.8) or of
pericardial friction rub prior to receiving placebo or indometh-
acm (mean number of days: placebo = 2.2 0.6 sE; indometh-
acm = 0.9 0.7 SE).
Initial mean cardiothoracic ratio (on chest x-ray) was similar
in the two groups (placebo = 0.61 0.01 SE; indomethacin =
0.58 0.02 SE) (P = NS). Large anterior and posterior
pericardial effusions were initially present in two patients in
each group. The remainder of the patients initially had no or
small pericardial effusions (less than 1 cm in diameter) mea-
sured by echocardiography in the supine position.
Fever on admission (oral temperature greater than 100°F) was
present in eight of 13(62%) of the patients receiving the placebo
Peripheral
white blood
count
(WBC/cc3)
65 8.1 20,600
Size of
initial
pericardial
effusion
large!
small b
NS).
Peripheral blood leukocytosis (10,000 WBC/cc) was present
in nine of 13 (69%) of the placebo patients and in five of 11
(45%) of the indomethacin patients (P NS). There was no
significant difference in mean serum concentrations of urea
nitrogen or creatinine concentrations (Table 1), or in hematocrit
value or serum calcium, phosphorus, albumin, or globulin
concentrations (not in Table 1) between the two groups.
Efficacy of treatment
All but two patients completed the scheduled course of
medication. One placebo patient, whose friction rub and chest
pain had completely cleared, discharged himself against medi-
cal advice on day 7 of treatment. He was readmitted to the
hospital 6 days later in the same asymptomatic clinical condi-
Male-
Patient Female
no. M/F
Prior
Age dialysis
years months
Temper- Serum urea Serum
ature nitrogen creatinine
oral mg/cl? mgldl
M 39 10 H Pneumonia
M 22 0 0 Infected shunt!
sepsis
0.75 P Peritonitis!
scieroderma
0.25 P None
5 H Pneumonia/sep-
44 14.4
172 27.6
11,100
11,200
+ 102
0 101.8
+ 101
0 99
+ 100.4
+ 100
+ 101.4
0 102.6
+ 99.2
0 99
+ 100.2
0 98
+ 98.8
128 16.6
47 9.6
49 11.4
76 11.2
56 19.4
138 13.3
66 12
73 12.5
86 24.5
S
S
S
L
S
S
S
L
S
S
S
S
S
10,100
9,200
10,900
15,500
3,200
8,800
16,800
10,600
5,900
Indomethacin
I F
2 F
3 M
4 M
5 M
6 F
7 F
68 1
20 9
68 3.5
28 39
21 20
26 8
22 1
78 11.2 13,500
8(62%) 100.3 0.4 83.3 11.8 14.8 1.6 11,300 1,260 2L/I1S7M/6F 46.2 4.6 6.9 2.8 7H/4P
P URI
P None
P Peritonitis
H None
H None
H Viral syndrome
P Hemolytic-ure-
mic syndrome
8 F 72 0 0 GI bleed/new
AV access
9 F 23 7 P Fever/pleural ef-
fusion
10 F 36 1 H Cortical necrosis
M 38 10 H Clotted bovine
graft
64 14,5
76 15.0
48 10.4
80 22.4
59 14.1
42 9.9
124 24.6
0 101
+ 99.8
0 102
0 102
+ 100.4
+ 99
+ 99.8
0 99.8
-f 99.6
+ 100.4
0 98.6
16,100
22,100
20,600
8,100
6,500
6,900
13,400
4M/7F 38.4 6.3 9.0 3.5 5H/5P
103 10.4 7,800
S
S
S
L
L
S
S
S
S
S
S
73 29.4
94 12.1
84 29.8
5,500
4,300
13,200
6(55%) 100.4 0.4 77.0 7.3 17.5 2.3 11,300 1,860 2L/9S
Abbreviations: H, hemodialysis; P, peritoneal dialysis; 0, none.
There was no statistical difference between the placebo and indomethacin groups for any characteristic; mean values are indicated SE.
b See Results for explanation.
the patients receiving indomethacin. There was no statistical and five of 11(45%) of the patients receiving indomethacin (P
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tion and completed his course of medication. One indomethacin
patient who developed gastrointestinal symptoms, thought pos-
sibly related to indomethacin, had medication discontinued on
day 7. By that time, all signs and symptoms of pericarditis had
permanently abated, and the echocardiogram was normal.
Since both patients had returned to "baseline" medical status
prior to discontinuing drug therapy, and since no "rebound" of
symptoms or signs occurred, it was elected, before the identity
of the drugs was known, to include these patients in the study.
In patients receiving the placebo, fever (100°F) persisted after
beginning the drug for 2 to 6 days in six patients; three other
patients developed fever while on the placebo and the remain-
der had no fever. In contrast, indomethacin was effective in
immediately alleviating fever in three of four patients (fever in a
fifth patient defervesed before indomethacin was given); and no
patient developed fever while receiving indomethacin. The
difference between the treatment groups is statistically signifi-
cant (P < 0,05, Mann-Whitney two sample test).
Duration of chest pain due to pericarditis was variable, but
usually brief in both groups of patients. Chest pain did not occur
at any time in two placebo and three indomethacin patients
(Fig. 1). Three patients in each group had chest pain lasting 3 or
more days following onset of therapy and only two patients,
both in the indomethacin group, had chest pain lasting longer
than 1 week. One of the latter patients required pericardiectomy
for relief of persistent pain. There was no statistical difference
between the groups regarding duration of chest pain (Mann-
Whitney two sample test, "U").
In both groups, duration of pericardial friction rub was
variable; however, friction rub usually persisted longer than
chest pain (Fig. 1). In some patients, friction rub would
disappear for many hours only to reappear later (not shown on
Fig. 1). There was no statistical difference between the indo-
methacin-treated group and the placebo group in the duration of
friction rub following initiation of therapy (placebo-treated
group: mean duration SE = 10.3 1.7 days; indomethacin-
treated group = 16.0 3.8 days) (Mann-Whitney two sample
test, ''U'').
The size of pericardial effusion measured by echocardiog-
raphy for each patient is shown in Figure 2. For the majority of
patients in both groups, the size of pericardial effusion did not
change substantially over the elapsed study period. Four pa-
tients, two in each group, had large effusions when entered in
the protocol. Of these patients, only one in the placebo group
had spontaneous resolution of the effusion during the study
period (Fig. 2).
Of the 11 patients receiving placebo with a "small" amount
of pericardial effusion initially, three had increases in size of
effusion to "large" amounts. Of the nine indomethacin-treated
patients with "small" effusion initially, one had a progression
of pericardial effusion to a "large" amount, and a second had
effusion enlarge to "moderate" in size. There was no difference
in the treatment groups regarding change in size of pericardial
effusion (Wilcoxon rank sum statistic).
Sequellae of pericarditis for the two groups of patients are
noted in Figure 2 and tabulated in Table 2. Three placebo
patients required surgical intervention—two as an emergency
procedure for acute tamponade, and one for a clinical syndrome
suggesting chronic tamponade. Two patients receiving indo-
methacin underwent surgical intervention—the first for acute
tamponade, and the second for persistent pericarditis with rub,
pain, and large anterior and posterior effusion. A third indo-
methacin patient with a friction rub associated with large
anterior and posterior effusions persisting for greater than 4
weeks was offered, but refused, surgical intervention. (This
patient was not included as requiring surgery in our statistical
analysis.) There was no difference between the two treatment
groups in the incidence of surgical intervention (x2test). There
was no growth of bacteria or fungi from any of the surgically
removed pericardial fluid or pericardial tissue, and all biochemi-
cal and histopathologic examinations were consistent with
"uremic pericarditis."
Spontaneous resolution of effusions eventually occurred in
three patients who, at the end of the study period, had moderate
or large amounts of pericardial effusion.
Two patients receiving indomethacin died during the study
period. One patient died 25 days after beginning the protocol
with clinical evidence of pericarditis. At autopsy he had a new
myocardial infarction and large pulmonary emboli. A second
patient had clinical evidence of pericarditis when he died 7 days
after beginning indomethacin. At autopsy he exhibited a cere-
bral vascular occlusion and pneumonia. One patient who had
received a placebo died of pneumonia 2.5 weeks after ending
the 4-week study. At the time of death there was no clinical
evidence of pericarditis; postmortem exam was not performed.
No side effects were attributable to indomethacin with cer-
tainty. Four patients receiving indomethacin had occasional
nausea and/or vomiting as did four control patients. One patient
had indomethacin discontinued after 8 days because of nausea
and vomiting. Since these symptoms had been intermittently
present before beginning the drug, and since they persisted
intermittently after discontinuance, it was felt that the symp-
toms were not drug-related. A drop in platelet count during the
course of treatment was seen in two patients who received
indomethacin: One from 80,000 to 58,000 platelets/mi blood; the
other from 120,000 to 83,000 platelets/mI blood.
Discussion
In 1975 Minuth et al [81 reported defervescence and abate-
ment of pain within 6 to 24 hr after beginning indomethacin, 25
mg, three to four times daily, in eight patients with uremic
pericarditis. Further, they reported disappearance of pericardi-
al rub in all patients in from I to 7 days after beginning
indomethacin, compared to 21 to 24 days in three patients not
treated with the drug. Finally, surgical intervention (including
pericardiocentesis) was required in only one of the eight pa-
tients who received indomethacin, as compared to two of the
three patients not so treated. Those authors concluded that
indomethacin was "effective in the treatment of the pericarditis
associated with dialysis and precludes the need for invasive
procedures." Although there subsequently has been wide-
spread interest in indomethacin for treatment of uremic pericar-
ditis [9—111, no rigorous controlled evaluation of indomethacin
for treatment of pericarditis has been reported.
In our double-blinded study, indomethacin, given in the same
dosage as Minuth et al, produced a prompt defervescence, but
had no apparent effect on other manifestations of uremic
pericarditis: chest pain, friction rub, or pericardial effusion.
Furthermore, discontinuation of indomethacin did not result in
"rebound" symptoms or signs of pericarditis as was previously
Fig. 1. Duration of pericardial friction rub and
pain in dialyzed patients with pericarditis.
Each bar represents one patient. Bars
followed by "S" or "t" represent patients
requiring surgical intervention, or dying, on
the post-treatment day indicated.
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Fig. 2. Size of pericardial effusion, by
echocardiogram, at entry into protocol and at
4 weeks. Each set of two circles represents a
single patient. Points followed by "S" or "t"
represent size of effusion at surgical
intervention or death, respectively. For
definitions of volume of pericardial effusion,
see Results.
Volume of
effusion
Large
Moderate
Small or
none
Indomethacin-treated
O 0 (S34)
Week
Placebo-treated
O OS OS/S /
00 00L i
o 1 2 3 4
Week
There are several possible explanations for the apparent lack
of efficacy of indomethacin in our study. First, although we
Indomethacin used the drug regimen described by Minuth et a!, it is possible
that a larger dose might have resulted in greater efficacy.11 Secondly, the numbers of patients in the two treatment groups
may not have been large enough to detect a small, but real,
improvement in some feature of pericarditis other than fever
(type 2 error). The apparent lack of efficacy of indomethacin in
our investigation might also be explained by the heterogeneous
nature of our patient population. At entry of patients into the
study, pericarditis was manifested in a variety of ways, with
only a few patients suffering from all of the major features of
pericarditis (rub, pain, fever, and effusion). Further, we includ-
ed in our study three patients with chronic renal failure who
were not yet dialyzed prior to the onset of pericarditis, as well
as patients dialyzed by both peritoneal and hemodialysis. Some
writers have suggested that 'uremic" or "predialysis" pericar-
(S5) Placebo-treated
S Rub
Pain
{S25)
_________ (t7)
(t44)
lndomethacin-treated
(S21)
Li_k I I I I I
(t28)
5
Study
drug
begun
5 10 16 20 25 30 35 40
Time, days
Table 2. Early sequellae of uremic pericarditis in patients receiving
indornethacin or placebo
Placebo
13
3
lb
Total patients
Surgical intervention
Death
Pericardiectomy or pericardiocentesis was used.
h No evidence of pericarditis was exhibited at the time of death.
Both patients had clinical evidence of pericarditis at the time of
death, but died of other causes.
reported [8]. Finally, indomethacin treatment was not associat-
ed with a reduction in frequency of surgical intervention or
mortality. Our data, therefore, do not support the contention
that indomethacin has any beneficial effect, except on fever, on
the natural history of uremic pericarditis.
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ditis is different from, and perhaps more benign than, pericardi-
tis developing in a regularly dialyzed patient [5, 61. However,
since pericarditis in these two settings is similar in clinical
presentation, pathology, and response to beginning or contin-
ued dialysis, we feel that there is little to justify considering
them as separate illnesses. In fact, the three predialysis patients
enrolled in our study did not differ from the remainder of their
cohort in any substantial way; one of the three patients required
surgical intervention. Other investigators have suggested a
reduced incidence and a more benign course of uremic pericar-
ditis in patients treated with peritoneal dialysis rather than
hemodialysis [4, 7]. Again, this distinction is based on clinical
impression rather than controlled studies and the presence of
nine peritoneal dialysis patients with pericarditis in our study
would seem to belie these suggestions. Nevertheless, our use of
such a mixed patient population makes it possible that we
missed some subset of patients in whom one or more of the
manifestations of pericarditis (aside from fever) might respond
favorably to indomethacin.
It is important to note that the patient population of Minuth et
a!, whose conclusions were opposite to ours, was also heteroge-
neous and even smaller in number. That population also includ-
ed patients without fever, rub, or pericardial effusion. Whether
all of their patients had been on regular dialysis immediately
preceeding pericarditis is not clear since two patients were
being treated with prednisone for renal transplant rejection
when pericarditis appeared. All patients were, however, treated
with hemodialysis. Twelve percent (one of eight) receiving
indomethacin required surgical intervention, a percentage simi-
lar to the 20% average figure reported by others [61 for this
complication, and similar to the 18 and 23% figures of our
indomethacin and placebo-treated groups. Conversely, 66%
(two of three) of the patients in the Minuth et a! study who did
not receive indomethacin required surgical intervention for
tamponade. This figure is higher than other studies and suggests
that the divergent conclusions of our report and that of the
Minuth et a! study may be due to the smaller number of patients
and the nonblinded, nonrandomized entry of patients into their
study.
Our data illustrate several features of the course of uremic
pericarditis which are generally not recognized. The wide range
of the duration of symptoms of uremic pericarditis is illustrated
in Figure 1, including a group of patients whose illness of
greater than 2 weeks might be termed "prolonged." This
feature of uremic pericarditis has not been previously stressed,
although Compty, Cohen, and Shapiro [1] reported a "pro-
longed course" (duration undefined) in 36% of patients with
uremic pericarditis. Although the chest pain of pericarditis may
last weeks, it usually subsides within days, while pericardial
friction rub usually takes longer to subside, as illustrated in
Figure 1. Either rub or pain may subsequently recur for a
variable period of time, and there is often a temporal dissocia-
tion between the presence of pericardial friction rub and chest
pain related to pericarditis.
Although it might be expected that cardiac tamponade would
more likely develop in patients with prolonged symptoms,
Figure 1 indicates that this was not necessarily the case. In fact,
the disappearance of pain or rub preceeded the development of
symptoms or tamponade by as many as 12 days in three of five
patients requiring surgical intervention. In each of these three
patients the amount of pericardial effusion was noted to in-
crease as pain or rub disappeared. Accordingly, our data
suggest that echocardiography should be performed in patients
in whom pericardial rub and chest pain have subsided, if any
clinical evidence of pericardial effusion is present.
As might be expected, it would appear from our data that a
large volume of pericardial effusion is an indicator of potential
tamponade. In our population, all patients requiring invasive
procedures (pericardiectomy and/or pericardiocentesis) had a
large effusion (anterior and posterior, by echocardiography). Of
eight patients who had a large effusion at some time in the
course of their illness, five required surgical intervention (four
because of tamponade) (a sixth, with persistent rub and a large
effusion, but without definite tamponade, refused surgery and
eventually improved clinically). Thus, it would appear that
echocardiographic evidence of persistent large effusions or
progressively enlarging effusion would be an important means
of predicting potential surgical intervention.
Despite the fact that many investigators have noted that the
majority of dialyzed patients with pericarditis are neither under-
dialyzed or especially "uremic," authors are almost unanimous
in advocating increased frequency of dialysis in the treatment of
pericarditis [1—3, 5—7]. Luft, Gilman, and Weyman [5] advocate
five times per week hemodialysis and Renfrew, Buselmeier,
and Kjellstrand [6] dialyze on a daily basis. We suspect that this
policy of "superdialysis" of patients already receiving dialysis
derives from the recognized benefits of dialyzing uremic pen-
carditis patients not yet in a chronic dialysis program. It does
not necessarily follow, however, and has never been demon-
strated, that "superdialysis" improves pericarditis in adequate-
ly dialyzed uremic patients. Prior to our study we had felt no
special benefits accrued from "superdialyzing" patients who
were already adequately dialyzed (for example, 5- to 6-hr
hemodialysis three times weekly), and, therefore, we did not
routinely increase weekly dialysis time in our patients. Since
our tamponade and mortality rates are in the middle of rates
previously reported, we surmised that no adverse effect result-
ed from our policy. However, it would seem essential to begin a
regular dialysis program in those uremic patients with pericardi-
tis not yet receiving adequate dialysis.
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